209 related articles for article (PubMed ID: 27681999)
1. Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement.
El-Galaly TC; Cheah CY; Hutchings M; Mikhaeel NG; Savage KJ; Sehn LH; Barrington S; Hansen JW; Poulsen MØ; Smith D; Rady K; Mylam KJ; Larsen TS; Holmberg S; Juul MB; Cordua S; Clausen MR; Jensen KB; Bøgsted M; Johnsen HE; Seymour JF; Connors JM; Brown PD; Villa D
Br J Haematol; 2016 Dec; 175(5):876-883. PubMed ID: 27681999
[TBL] [Abstract][Full Text] [Related]
2. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
3. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era.
Kridel R; Telio D; Villa D; Sehn LH; Gerrie AS; Shenkier T; Klasa R; Slack GW; Tan K; Gascoyne RD; Connors JM; Savage KJ
Br J Haematol; 2017 Jan; 176(2):210-221. PubMed ID: 27739058
[TBL] [Abstract][Full Text] [Related]
4. Secondary central nervous system relapse in diffuse large B cell lymphoma in a resource limited country: result from the Thailand nationwide multi-institutional registry.
Wudhikarn K; Bunworasate U; Julamanee J; Lekhakula A; Chuncharunee S; Niparuck P; Ekwattanakit S; Khuhapinant A; Norasetthada L; Nawarawong W; Makruasi N; Kanitsap N; Sirijerachai C; Chansung K; Wong P; Numbenjapon T; Prayongratana K; Suwanban T; Wongkhantee S; Praditsuktavorn P; Intragumtornchai T;
Ann Hematol; 2017 Jan; 96(1):57-64. PubMed ID: 27752821
[TBL] [Abstract][Full Text] [Related]
5. Intravenous but not intrathecal central nervous system-directed chemotherapy improves survival in patients with testicular diffuse large B-cell lymphoma.
Mannisto S; Vähämurto P; Pollari M; Clausen MR; Jyrkkiö S; Kellokumpu-Lehtinen PL; Kovanen P; Karjalainen-Lindsberg ML; d'Amore F; Leppä S
Eur J Cancer; 2019 Jul; 115():27-36. PubMed ID: 31082690
[TBL] [Abstract][Full Text] [Related]
6. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma.
El-Galaly TC; Cheah CY; Bendtsen MD; Nowakowski GS; Kansara R; Savage KJ; Connors JM; Sehn LH; Goldschmidt N; Shaulov A; Farooq U; Link BK; Ferreri AJM; Calimeri T; Cecchetti C; Dann EJ; Thompson CA; Inbar T; Maurer MJ; Gade IL; Juul MB; Hansen JW; Holmberg S; Larsen TS; Cordua S; Mikhaeel NG; Hutchings M; Seymour JF; Clausen MR; Smith D; Opat S; Gilbertson M; Thanarajasingam G; Villa D
Eur J Cancer; 2018 Apr; 93():57-68. PubMed ID: 29477102
[TBL] [Abstract][Full Text] [Related]
7. Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma.
Kim SJ; Oh SY; Kim JS; Kim H; Lee GW; Won JH; Shin HJ; Yang DH; Choi CW; Park J; Kim WS; Suh C
Ann Hematol; 2011 May; 90(5):539-46. PubMed ID: 20960190
[TBL] [Abstract][Full Text] [Related]
8. Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience.
Shimazu Y; Notohara K; Ueda Y
Int J Hematol; 2009 Jun; 89(5):577-83. PubMed ID: 19353238
[TBL] [Abstract][Full Text] [Related]
9. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
Tai WM; Chung J; Tang PL; Koo YX; Hou X; Tay KW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
[TBL] [Abstract][Full Text] [Related]
10. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era.
Ferreri AJ; Bruno-Ventre M; Donadoni G; Ponzoni M; Citterio G; Foppoli M; Vignati A; Scarfò L; Sassone M; Govi S; Caligaris-Cappio F
Br J Haematol; 2015 Mar; 168(5):654-62. PubMed ID: 25312994
[TBL] [Abstract][Full Text] [Related]
11. Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.
Ollila TA; Olszewski AJ
Curr Treat Options Oncol; 2018 Jun; 19(8):38. PubMed ID: 29931605
[TBL] [Abstract][Full Text] [Related]
12. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
Rasmussen PK
Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
[TBL] [Abstract][Full Text] [Related]
13. Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy.
Yhim HY; Kim JS; Kang HJ; Kim SJ; Kim WS; Choi CW; Eom HS; Kim JA; Lee JH; Won JH; Shim H; Huh J; Lee DH; Suh C; Kwak JY
Int J Cancer; 2012 Jul; 131(1):235-43. PubMed ID: 21823120
[TBL] [Abstract][Full Text] [Related]
14. Clinical features, management and prognosis of multifocal primary bone lymphoma: a retrospective study of the international extranodal lymphoma study group (the IELSG 14 study).
Messina C; Ferreri AJ; Govi S; Bruno-Ventre M; Gracia Medina EA; Porter D; Radford J; Heo DS; Park HY; Pro B; Jayamohan J; Visco C; Scarfò L; Zucca E; Gospodarowicz M; Christie D;
Br J Haematol; 2014 Mar; 164(6):834-40. PubMed ID: 24383942
[TBL] [Abstract][Full Text] [Related]
15. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
Guirguis HR; Cheung MC; Mahrous M; Piliotis E; Berinstein N; Imrie KR; Zhang L; Buckstein R
Br J Haematol; 2012 Oct; 159(1):39-49. PubMed ID: 22849793
[TBL] [Abstract][Full Text] [Related]
16. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma.
Arkenau HT; Chong G; Cunningham D; Watkins D; Agarwal R; Sirohi B; Trumper M; Norman A; Wotherspoon A; Horwich A
Ann Oncol; 2007 Mar; 18(3):541-5. PubMed ID: 17164228
[TBL] [Abstract][Full Text] [Related]
17. Influence of Rituximab on Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma and Role of Prophylaxis--A Systematic Review of Prospective Studies.
Ghose A; Elias HK; Guha G; Yellu M; Kundu R; Latif T
Clin Lymphoma Myeloma Leuk; 2015 Aug; 15(8):451-7. PubMed ID: 25816933
[TBL] [Abstract][Full Text] [Related]
18. Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse.
Villa D; Connors JM; Sehn LH; Gascoyne RD; Savage KJ
Haematologica; 2011 Jul; 96(7):1002-7. PubMed ID: 21486867
[TBL] [Abstract][Full Text] [Related]
19. Similar chemokine receptor profiles in lymphomas with central nervous system involvement - possible biomarkers for patient selection for central nervous system prophylaxis, a retrospective study.
Lemma SA; Pasanen AK; Haapasaari KM; Sippola A; Sormunen R; Soini Y; Jantunen E; Koivunen P; Salokorpi N; Bloigu R; Turpeenniemi-Hujanen T; Kuittinen O
Eur J Haematol; 2016 May; 96(5):492-501. PubMed ID: 26153511
[TBL] [Abstract][Full Text] [Related]
20. Ocular adnexal diffuse large B-cell lymphoma: a multicenter international study.
Munch-Petersen HD; Rasmussen PK; Coupland SE; Esmaeli B; Finger PT; Graue GF; Grossniklaus HE; Honavar SG; Khong JJ; McKelvie PA; Mulay K; Prause JU; Ralfkiaer E; Sjö LD; Sniegowski MC; Vemuganti GK; Heegaard S
JAMA Ophthalmol; 2015 Feb; 133(2):165-73. PubMed ID: 25393033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
